Clinical Trials
2 trialsNCT05693090 2023-03-06
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Phase 1 Withdrawn
NCT00054470 2012-06-29
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn